LLY vs PFE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PFE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

Full PFE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation (about 42x trailing and 27x forward earnings, and roughly 14x sales, as of October 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LLY if you believe its drivers more; PFE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and PFE guides.

LLY. At about $1,266 a share on October 16, 2026, Eli Lilly is valued near $1.13 trillion, roughly 42x trailing earnings and 27x the roughly $47.48 in EPS analysts expect for 2027. That premium rests on revenue growth near 48% in the latest quarter and margins (about 54% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the October 29 third-quarter report (consensus about $7.16 EPS on $22.45 billion revenue) is the next data point.

PFE. Pfizer trades at about 10x forward earnings and a dividend yield near 5.8%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges rather than weak operations. Even after a 17.5% gain in 2026 the shares sit right around the 26 analysts' mean target of about $29, so the valuation now balances substantial cash generation against flat-to-lower consensus earnings.

Headline figures (approximate, October 2026): LLY shows revenue (ttm) ~$79.7 billion, q2 2026 revenue ~$23.0 billion (up ~48% YoY), q2 2026 eps $8.38 vs ~$6.58 est., gross / operating margin (ttm) ~83% / ~54%; PFE shows revenue (ttm) ~$63.7 billion (Q2 2026 +~2.6% YoY), operating margin ~28%, net income (ttm, gaap) ~$4.3 billion, q2 2026 adjusted eps ~$0.77 vs ~$0.68 consensus.

LLY and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and PFE exposure against your real portfolio. It is not an investment adviser.